|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In particular, brain-derived neurotrophic factor (BDNF) has been shown to exert trophic and protective effects on dopaminergic neurons, the cell type known to degenerate in Parkinson's disease.
|
8590062 |
1995 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, both control and PD neurons displayed a direct relationship between the density of BDNF mRNA expression per square micrometer of cell surface and neuronal size (r(2) = 0.93, P </= 0.00001) which was lost only in PD neurons expressing the lowest levels of BDNF mRNA.
|
11031089 |
2000 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results provide genetic evidence supporting a role for BDNF in the pathogenesis of Parkinson's disease.
|
11782995 |
2002 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Brain-derived neurotrophic factor controls dopamine D3 receptor expression: therapeutic implications in Parkinson's disease.
|
14623353 |
2003 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Thus, our negative findings suggest that it is unlikely that the BDNF Val66Met polymorphism plays a major role in the pathogenesis of PD in the Chinese population.
|
14642442 |
2003 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
To determine the role of the BDNF gene in the development of familial and sporadic PD, we sequenced the promoter region of the gene using genomic DNA from patients with familial PD.
|
15120095 |
2004 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
To determine the role of the BDNF gene in the development of familial and sporadic PD, we sequenced the promoter region of the gene using genomic DNA from patients with familial PD.
|
15120095 |
2004 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association studies of BDNF variants reveal no associations with Parkinson's disease.
|
15666411 |
2005 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
A treatment for PD may be possible with dual gene therapy that seeks both to replace striatal TH gene expression with TH gene therapy, and to halt or reverse neurodegeneration of the nigro-striatal tract with neurotrophin gene therapy.
|
15717064 |
2005 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson's disease.
|
15772739 |
2005 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We studied two genetic polymorphisms (240C/T and 480G/A) of the brain-derived neurotrophic factor (BDNF) gene in Japanese patients with Alzheimer's disease (AD, n = 172), Parkinson's disease (PD, n = 327), and multiple system atrophy (MSA, n = 122), as well as controls (n = 275).
|
15838855 |
2005 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The meta-analysis results suggest that the involvement of the BDNF gene in susceptibility to PD merits further exploration with larger and more rigorous population association studies.
|
16172806 |
2005 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
These findings suggest that BDNF may influence PD onset age.
|
16344533 |
2005 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, it seems that the BDNF gene does not contribute significantly to the risk of AD or PD in Finnish patients.
|
16565926 |
2006 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To date, there have been several conflicting reports on the correlation between AD or PD and Val66Met or C270T polymorphism in the BDNF promoter region, although no data on this relationship have been published with respect to dementia with Lewy bodies (DLB).
|
16899999 |
2006 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, our results do not provide statistically significant evidence that common genetic variability in BDNF would associate with the risk for PD in the Caucasian populations studied here.
|
17229524 |
2007 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Neither BDNF nor NR4A2 polymorphism influences PD onset age.
|
17427185 |
2007 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Neither BDNF nor NR4A2 polymorphism influences PD onset age.
|
17427185 |
2007 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Gene-based candidates for Parkinson's disease (PD) include the ubiquitin-proteosome system, scavengers of reactive oxygen species, brain-derived neurotrophic factor (BDNF), its receptor, TrkB, and downstream target early growth response 1, Nurr-1, and signaling through protein kinase C and RAS pathways.
|
18923405 |
2009 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The influence of a common functional polymorphism of the BDNF gene on the risk of developing dyskinesias in a large cohort of patients with PD (n = 315), who were independently and variably treated with levodopa and/or other dopaminergic treatments, was investigated.
|
18977816 |
2009 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
LHGDN |
The influence of a common functional polymorphism of the BDNF gene on the risk of developing dyskinesias in a large cohort of patients with PD (n = 315), who were independently and variably treated with levodopa and/or other dopaminergic treatments, was investigated.
|
18977816 |
2009 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
CTD_human |
IGF-I and IGF-II resistance was present in DLB but not PD frontal cortex, and associated with reduced expression of Hu, nerve growth factor, and Trk neurotrophin receptors, and increased levels of glial fibrillary acidic protein, alpha-synuclein, dopamine-beta-hydroxylase, 4-hydroxy-2-nonenal (HNE), and ubiquitin immunoreactivity.
|
19276553 |
2009 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
IGF-I and IGF-II resistance was present in DLB but not PD frontal cortex, and associated with reduced expression of Hu, nerve growth factor, and Trk neurotrophin receptors, and increased levels of glial fibrillary acidic protein, alpha-synuclein, dopamine-beta-hydroxylase, 4-hydroxy-2-nonenal (HNE), and ubiquitin immunoreactivity.
|
19276553 |
2009 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Changes in the levels and activities of neurotrophic factors, such as brain-derived neurotrophic factor (BDNF), have been described in a number of neurodegenerative disorders, including Huntington disease, Alzheimer disease and Parkinson disease.
|
19498435 |
2009 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The BDNF polymorphisms were analyzed in 294 Italian patients with PD; results were compared to those obtained in 233 age- and sex-matched healthy controls (HC) enrolled from two tertiary centres in Italy.
|
19538209 |
2009 |